• Petros Pharmaceuticals posted a net loss of USD 987,036 for the quarter ended March 31, 2026, narrowing from USD 2.26 million a year earlier.
• Selling, general and administrative expense fell 30% to USD 1.03 million, driving an operating loss of USD 1.03 million.
• Other income dropped to USD 40,143 from USD 258,808 as warrant-related gains recorded in the prior-year quarter did not recur.
• Cash and cash equivalents totaled about USD 4.4 million at quarter-end, while net cash used in operating activities from continuing operations improved to USD 784,272 from USD 1.49 million.
• Management said substantial doubt exists about its ability to continue as a going concern within one year, with efforts focused on raising additional financing and developing its Rx-to-OTC switch technology platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-060359), on May 13, 2026, and is solely responsible for the information contained therein.